UAB Hematology Review 2021
New Therapies for Sickle Cell Disease in 2021: Crizanlizumab vs. Placebo, Voxelotor+Placebo, Identifying Appropriate Treatment
By
UAB Hematology Review 2021
FEATURING
Julie Kanter
By
UAB Hematology Review 2021
FEATURING
Julie Kanter
Login to view comments.
Click here to Login